Cardiology · Medical Literature
Percutaneous Coronary Intervention in Frail Patients Undergoing Transcatheter Aortic Valve Replacement: A NOTION-3 Substudy.
Abstract
Frailty is an important predictor of outcomes in patients with coronary artery disease (CAD) and following transcatheter aortic valve replacement (TAVR). The NOTION-3 (Third Nordic Aortic Valve Intervention) trial demonstrated that performing percutaneous coronary intervention (PCI) in addition to TAVR reduced the risk for major adverse cardiac events (MACE). Whether this benefit applies to frail patients remains uncertain. The aim of this study was to evaluate efficacy and safety of PCI in frail TAVR patients with CAD. NOTION-3 was an international, open-label, randomized superiority trial enrolling patients with CAD and severe aortic stenosis undergoing TAVR. Patients were randomized 1:1 to PCI or conservative treatment. Frailty was assessed post hoc using a calculated frailty score derived from baseline data on symptom-related limitations, daily function, and quality of life. Primary endpoint was a composite of all-cause mortality, myocardial infarction (MI), and urgent coronary revascularization. Safety endpoints included bleeding and acute kidney injury. Frailty data were available for 407 patients (90%), of whom 130 (32%) were frail. During median follow-up of 2 years (Q1-Q3: 1-4 years), PCI reduced MACE in nonfrail patients (15% vs 33%; HR: 0.42; 95% CI: 0.25-0.69; P < 0.001), as well as death of any cause (P = 0.019), MI (P = 0.004), and urgent revascularization (P = 0.005). No differences were observed in frail patients. In contrast, frail patients undergoing PCI had more bleeding events (HR: 2.51; 95% CI: 1.23-5.11; P = 0.011). In nonfrail patients with CAD undergoing TAVR, PCI lowered the risk for MACE, all-cause mortality, and MI compared to conservative treatment. In frail patients, PCI increased bleeding without clinical benefit. These findings require confirmation in larger prospective studies.
Clinical relevance
In patients with coronary artery disease and severe aortic stenosis undergoing TAVR, does the addition of PCI reduce major adverse cardiac events (MACE) in frail patients compared with conservative management, and what is the associated safety profile? __SNAPSHOT__ {"studyDesign":"Post hoc subgroup analysis of a pre-specified frailty substudy within NOTION-3, an international, open-label, randomized controlled superiority trial","setting":"Multinational (Denmark, Finland, Latvia, Sweden); 12 centers","sampleSize":"407 of 451 parent-trial patients had frailty data available (90%); frail subgroup: n=130 (32%); nonfrail subgroup: n=277 (68%)","population":"Adults with severe aortic stenosis and at least one physiologically significant, PCI-eligible coronary artery disease lesion selected for TAVR; mean age approximately 81 years, ~33% female; frailty assessed post hoc via a calculated composite frailty score derived from symptom-related limitations, daily function, and quality of life","intervention":"Percutaneous coronary intervention (PCI) in addition to TAVR","comparator":"Conservative treatment (TAVR alone without PCI)","primaryOutcome":"Composite of all-cause mortality, myocardial infarction (MI), and urgent coronary revascularization","followUp":"Median 2 years (IQR: 1–4 years)","fundingSource":"Not reported in available abstract; parent NOTION-3 trial was investigator-initiated (Copenhagen University Hospital); full sponsorship details not confirmed from abstract alone"}
Key findings
Among nonfrail patients (n=277), PCI significantly reduced MACE compared with conservative treatment (15% vs. 33%; HR 0.42; 95% CI 0.25–0.69; P<0.001). The NNT to prevent one MACE event in nonfrail patients was approximately 6 (calculated: 1/[0.33–0.15]). Individual MACE components also favored PCI in nonfrail patients: all-cause mortality (P=0.019), MI (P=0.004), and urgent revascularization (P=0.005); absolute event rates for these individual components were not reported in the available abstract. Among frail patients (n=130), no statistically significant differences in MACE or any of its components were observed between PCI and conservative treatment. Critically, PCI was associated with a significantly higher rate of bleeding events in frail patients (HR 2.51; 95% CI 1.23–5.11; P=0.011). Absolute bleeding event rates in the frail subgroup were not reported in the available abstract. No meaningful differences in acute kidney injury were reported between groups in either frailty stratum.
Practice implications
This substudy provides clinically important signal that the MACE benefit of routine PCI in TAVR patients observed in the parent NOTION-3 trial appears to be concentrated exclusively in nonfrail patients, and that frail patients may be harmed through excess bleeding without offsetting clinical benefit. The frailty assessment was performed post hoc using a derived score rather than a prospectively validated bedside frailty instrument (e.g., Clinical Frailty Scale, Fried phenotype), which introduces uncertainty about classification accuracy and reproducibility. Because this is a subgroup analysis — not the primary randomized comparison — causal inference is limited, and the frail subgroup (n=130) was likely underpowered to detect a moderate treatment effect had one been present. The finding of increased bleeding risk in frail patients is biologically plausible given reduced physiological reserve, the hemostatic burden of dual antiplatelet therapy, and the cumulative procedural exposure of combined PCI+TAVR. These data do not establish definitively that PCI is harmful in all frail TAVR patients, but they strongly caution against a one-size-fits-all approach to routine revascularization in this population. Larger prospective studies with prespecified frailty stratification are needed before definitive practice recommendations can be made for frail patients. Only the abstract was available for review; full methodology, covariate adjustment details, and absolute event rate data for all endpoints require evaluation of the complete manuscript. __LIMITATIONS__ Post hoc frailty assessment using a derived composite score rather than a prospectively validated frailty instrument limits reproducibility and raises the possibility of frailty misclassification,Subgroup analysis is exploratory by design; the frail subgroup (n=130) was likely underpowered to detect a modest but clinically meaningful treatment effect, increasing the risk of a false-negative result,Open-label trial design introduces ascertainment and management bias, particularly relevant for subjective endpoints and for decisions about post-procedural care in frail patients,Generalizability is limited to a Northern European, predominantly white, intermediate-surgical-risk TAVR population; findings may not apply to higher-risk or more diverse populations,Frailty data were unavailable for 10% of the parent trial cohort, introducing potential selection bias in the substudy population,Interaction p-value between frailty status and PCI treatment effect was not reported in the available abstract, limiting formal statistical confirmation of effect modification,Surrogate frailty phenotyping derived from baseline quality-of-life and functional data may conflate frailty with disability or comorbidity burden rather than capturing true biological aging,Median follow-up of 2 years may be insufficient to capture late mortality differences, particularly relevant in a frail elderly population with competing risks,Full manuscript not available for review; detailed covariate adjustment, prespecified subgroup definitions, and absolute event rates for all endpoints could not be confirmed __BOTTOM_LINE_CATEGORY__ potentially_practice_informing __BOTTOM_LINE__ In TAVR patients with concomitant CAD, PCI substantially reduced MACE in nonfrail patients but conferred no detectable clinical benefit and significantly increased bleeding risk in frail patients. Until prospective data with validated frailty instruments are available, routine PCI should not be applied uniformly across all frailty strata, and formal frailty assessment should be integrated into the TAVR Heart Team decision-making process to individualize revascularization strategy.